| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/17/2003 | US20030134818 Lyophilizable and enhanced compacted nucleic acids |
| 07/17/2003 | US20030134811 Methods and compositions comprising hydroxyapatite useful for the administration of therapeutic agents |
| 07/17/2003 | US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as |
| 07/17/2003 | US20030134805 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| 07/17/2003 | US20030134804 Rehydrating formulation |
| 07/17/2003 | US20030134803 Contraceptive devices that use sulfonated compounds that interact with sperm to inhibit fertilization. Natural contraceptive methods, compositions and contraceptive devices are also included. These natural contraceptives use |
| 07/17/2003 | US20030134800 Physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. composition weight, (2) hydroxynaphthoic acid |
| 07/17/2003 | US20030134778 Pharmaceutical composition comprising factor VIII and neutral liposomes |
| 07/17/2003 | US20030134424 For implanting/transfecting monodispersed silicon particles joined to DNA into target tissue, cell or the blood stream |
| 07/17/2003 | US20030134423 Lipid aggregates (liposomes) for transfection of nucleic acids |
| 07/17/2003 | US20030134312 Utilizes at least one primer for analysis; automatic for massed screening and the discovery of sequence variants of known virons, undetected virons and others |
| 07/17/2003 | US20030134120 Stabilized by heat treatment with alkaline solution; for clothing having bactericidal, deodorizing, and hemostatic activity |
| 07/17/2003 | US20030133998 Comprising diphenhydramine HCl, belladonna tincture, buffer, flavourants, absolute alcohol, wherein alcohol concentrate comprises 2.8%-3.2% by volume |
| 07/17/2003 | US20030133991 Composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in carrier, which, when applied to open wound, modulates activity of MMP-2 and/or MMP- 9 in wound; ulcer treatment |
| 07/17/2003 | US20030133989 Skin care products containing whole egg |
| 07/17/2003 | US20030133988 Immunomodulation accomplished by administration of immunomodulatory polynucleotide/microcarrier complexes comprising 3-6 mer immunomodulatory oligonucleotides |
| 07/17/2003 | US20030133987 Preparing emulsion comprising water and templating agent, preparing drug mixture, combining template emulsion with drug-containing mixture to form template emulsion loaded with drug particles; faster dissolution, bioavailability |
| 07/17/2003 | US20030133986 Compositions for stabilizing poly (carboxylic acids) |
| 07/17/2003 | US20030133985 Controlled release oral dosage forms; data obtained using disintegration test such as the established USP Disintegration Test, rather than the results obtained using a standard USP Dissolution Test, as is conventionally done |
| 07/17/2003 | US20030133984 Comprising poorly water soluble drug, solubilizing component, and surfactant which is semisolid or solid; drug may e.g. be a cyclosporin or a macrolide; immunosuppressants |
| 07/17/2003 | US20030133983 Comprises core and enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a derivative thereof; treatment of ulcerative colitis and Crohn's disease |
| 07/17/2003 | US20030133982 Suitable for administration of a wide range of therapeutically active medicaments, especially those that are water-soluble; ethylcellulose core, active agent, hydrophobic polymer coating |
| 07/17/2003 | US20030133981 Extended release formulations of erythromycin derivatives |
| 07/17/2003 | US20030133980 Biocompatible polymer blends and uses thereof |
| 07/17/2003 | US20030133979 Device for the sustained release of aggregation-stabilized, biologically active agent |
| 07/17/2003 | US20030133978 Pharmaceutical formulations |
| 07/17/2003 | US20030133977 Method of systemically delivering SSRIs |
| 07/17/2003 | US20030133976 Effervescent drug delivery system for oral administration |
| 07/17/2003 | US20030133975 Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| 07/17/2003 | US20030133974 Gelatin-encapsulated sertraline and a water immiscible vehicle shorten Tmax and/or reduce side effects and/or decrease sertraline precipitation in chloride ion-containing environments |
| 07/17/2003 | US20030133973 Vesicle-forming lipid and a vesicle-forming lipid derivatized with a hydrophilic polymer |
| 07/17/2003 | US20030133971 Positively charged and neutral lipids facilitates cellular uptake; liposomes |
| 07/17/2003 | US20030133970 Occlusive transdermal therapeutic system with a non-occlusive backing layer |
| 07/17/2003 | US20030133969 Topical agent capable of disrupting membrane or protein conformation in a target cell, tissue or microbe; does not contain nonoxynol-9, benzalkonium chloride or menfegol |
| 07/17/2003 | US20030133964 Polymeric delivery formulations of leuprolide with improved efficacy |
| 07/17/2003 | US20030133959 Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
| 07/17/2003 | US20030133955 Methods and compositions useful for administration of chemotherapeutic agents |
| 07/17/2003 | US20030133954 Medical compositions for intravesical treatment of bladder cancer |
| 07/17/2003 | US20030133953 Complexing a biologically active agent with a perturbant to reversibly transform and exposing a membrane or bilayer to the supramolecular complex |
| 07/17/2003 | US20030133950 Inducing a desired T helper lymphocyte regulated immune response by delivering an immunogen to a preselected region of the gastrointestinal tract of a patient |
| 07/17/2003 | US20030133940 Medicaments for chemotherapeutic treatment of disease |
| 07/17/2003 | US20030133925 Monobactam compositions and methods of use thereof |
| 07/17/2003 | US20030133905 Composition for treating contact lenses in the eye |
| 07/17/2003 | US20030133903 Compositions for treatment of prostate cancers and methods of making and using the same |
| 07/17/2003 | US20030133902 Method of making phosphate-binding polymers for oral administration |
| 07/17/2003 | US20030133897 Long-lasting styling mousse |
| 07/17/2003 | US20030133880 Powdery pharmaceutical compositions for inhalation |
| 07/17/2003 | US20030133879 Therapeutic composition for pulmonary delivery |
| 07/17/2003 | US20030133877 For inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation; administering to patient using intranasal drug delivery device |
| 07/17/2003 | US20030133876 Preparation of further diagnostic agents |
| 07/17/2003 | US20030133872 Radiopharmaceutical agent for the treatment of early stage cancer |
| 07/17/2003 | US20030133357 Method and apparatus for preparing microparticles using in-line solvent extraction |
| 07/17/2003 | US20030133355 Preparation of liquid dispersions |
| 07/17/2003 | US20030131843 Open-celled substrates for drug delivery |
| 07/17/2003 | US20030131652 Determination of gas solubility, entrained gas content, and true liquid density in manufacturing processes |
| 07/17/2003 | US20030131532 Floral packaging material having great masters prints thereon |
| 07/17/2003 | CA2473106A1 Pravastatin pharmaceutical formulations and methods of their use |
| 07/17/2003 | CA2473081A1 Use of phospholipids in peritoneal dialysis |
| 07/17/2003 | CA2472585A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | CA2472383A1 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 07/17/2003 | CA2472198A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 07/17/2003 | CA2472098A1 Apparatuses and methods for automatically assessing and monitoring a patient's responsiveness |
| 07/17/2003 | CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | CA2471948A1 Novel pharmaceutical dosage forms and method for producing same |
| 07/17/2003 | CA2471715A1 A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof |
| 07/17/2003 | CA2471657A1 Methods for improving the aesthetic appearance of skin |
| 07/17/2003 | CA2471572A1 Taxane based compositions and methods of use |
| 07/17/2003 | CA2471490A1 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders |
| 07/17/2003 | CA2471211A1 Drug delivery system for sustained delivery of glipizide |
| 07/17/2003 | CA2470496A1 A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
| 07/17/2003 | CA2470495A1 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 07/17/2003 | CA2469052A1 Transdifferentiation of pancreatic acinar cells |
| 07/17/2003 | CA2467829A1 Feminine care products for the delivery of therapeutic substances |
| 07/17/2003 | CA2460343A1 Delivery of caffeine through an inhalation route |
| 07/16/2003 | EP1327463A1 Gel comprising Cetirizine and Loratadine for topical application |
| 07/16/2003 | EP1327453A1 Stable taurolidine electrolyte solutions |
| 07/16/2003 | EP1327452A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 07/16/2003 | EP1327451A1 Adjuvants for vaccines |
| 07/16/2003 | EP1327449A1 Remedies for ischemic diseases |
| 07/16/2003 | EP1327446A1 Controlled release oxycodone compositions |
| 07/16/2003 | EP1327445A1 Controlled release oxycodone compositions |
| 07/16/2003 | EP1327442A1 Process for producing gel sheet for application to living body, gel sheet for application to living body obtained by the production process, and method of skin care with the same |
| 07/16/2003 | EP1327441A1 Chewing gum composition for eliminating nicotine, containing plant extracts and polyphenols such as catechin or quercetin |
| 07/16/2003 | EP1327440A1 Oral preparations with favorable disintegration characteristics |
| 07/16/2003 | EP1327434A1 Nanoemulsion comprising metabolites of ginseng saponin and a skin-care composition for anti-aging containing the same |
| 07/16/2003 | EP1327149A2 Methods of high-throughput screening for internalizing antibodies |
| 07/16/2003 | EP1326894A2 Novel tumor-associated marker |
| 07/16/2003 | EP1326862A1 Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
| 07/16/2003 | EP1326840A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/16/2003 | EP1326838A1 Novel crystalline forms of a factor xa inhibitor |
| 07/16/2003 | EP1326834A2 2-substituted heterocyclic compounds |
| 07/16/2003 | EP1326833A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/16/2003 | EP1326825A2 Compounds and compositions for delivering active agents |
| 07/16/2003 | EP1326705A1 Granules obtained by drying a multiple emulsion |
| 07/16/2003 | EP1326644A1 Absorption enhancers |
| 07/16/2003 | EP1326639A1 Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol |
| 07/16/2003 | EP1326633A1 Composition comprising immunogenic microparticles |
| 07/16/2003 | EP1326632A2 Agents for the treatment of viral infections |
| 07/16/2003 | EP1326624A1 Method for producing phyllanthus extracts |
| 07/16/2003 | EP1326609A2 Stable oral formulation containing benzimidazole derivative |